Category: Injectable Medication

Amylin Lilly Logo

Lilly and Amylin Type 2 Diabetes Drug, Bydureon, Approved for Marketing in Europe

The European Commission has granted marketing authorization to Eli Lilly, Amylin Pharmaceuticals and Alkermes' type 2 diabetes drug Bydureon (exenatide extended-release for injectable suspension). Bydureon is a glucagon-like peptide-1 (GLP-1) receptor agonist, and is the first once-weekly treatment for type 2 diabetes. It delivers glycemic control in a single weekly dose and is indicated for the treatment of type 2 diabetes in adult patients...
0 Shares
Novo Nordisk

Novo Nordisk Issues Letter Reminding Healthcare Professionals of Victoza Risks

Novo Nordisk issued a letter reminding healthcare professionals of important safety information about the type 2 diabetes drug Victoza (liraglutide [rDNA origin]). The letter was issued because a recent assessment of healthcare providers showed that some primary care providers are not fully aware of the serious risks associated with the use of Victoza...
0 Shares
Amylin Lilly Logo

Bydureon Receives Positive Opinion From The European Medicines Agency

Eli Lilly and Company, Amylin Pharmaceuticals and Alkermes announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of Bydureon for injection in the European Union for the treatment of type 2 diabetes in combination with...
0 Shares
NovoNordiskLogo

Victoza More Effective Than Competitors New Study Shows

A new meta study presented by Novo Nordisk at the 20th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists (AACE) shows that regardless of baseline A1C, once-daily Victoza (liraglutide [rDNA origin] injection) 1.8 mg consistently helped more patients achieve blood sugar control than...
0 Shares
Novo Nordisk Logo

Victoza Approved for Treatment of Type 2 Diabetes in China

The Chinese State Food and Drug Administration (SFDA) has approved Victoza for the treatment of type 2 diabetes. Diabetes is a rapidly growing disease in China, and Victoza offers a unique treatment option by effectively reducing HbA1c and weight with a low risk of hypoglycemia in people with type 2 diabetes inadequately controlled by oral anti-diabetic agents...
0 Shares